5.1 Mechanical Ventilator Modes & Advanced Breath Delivery

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery

Key Takeaways Explain This Topic AI

Ventilator breaths are defined by phase variables: trigger (time vs flow/pressure), limit (variable constrained during delivery), and cycle (terminating variable: volume, time, or flow).

Volume Control (VC-CMV) delivers a guaranteed tidal volume with variable airway pressure, while Pressure Control (PC-CMV) maintains a fixed peak pressure with variable tidal volume dependent on compliance and resistance.

In VC-CMV with constant flow, plateau pressure measured during an end-inspiratory pause reflects alveolar pressure and static respiratory compliance, with driving pressure target under 14 to 15 cmH2O.

Airway Pressure Release Ventilation (APRV) provides continuous CPAP (P_high) with brief releases (P_low), requiring T_low titration to truncate expiratory flow at 75% of peak expiratory flow to prevent alveolar derecruitment.

Proportional assist modes (PAV+ and NAVA) adapt ventilatory work dynamically; NAVA utilizes crural diaphragmatic electrical activity (Edi) to eliminate pneumatic trigger delays.

Last updated: October 2026

Mechanical ventilation is a core supportive intervention in critical care medicine. Optimal management requires a deep mechanistic comprehension of the physical equations of motion, breath-delivery algorithms, and the physiologic consequences of positive pressure on respiratory and cardiovascular dynamics. Selecting the appropriate ventilator mode demands balancing lung-protective ventilation goals against patient work of breathing, gas exchange efficiency, and patient-ventilator synchrony.

1. Physical Principles & Phase Variables

Every mechanical breath delivered by a positive-pressure ventilator is governed by the classical equation of motion for the respiratory system :

P vent + P mus = V ˙ × R aw + V C rs + PEEP total P_{\text{vent}} + P_{\text{mus}} = \dot{V} \times R_{\text{aw}} + \frac{V}{C_{\text{rs}}} + \text{PEEP}_{\text{total}} P vent ​ + P mus ​ = V ˙ × R aw ​ + C rs ​ V ​ + PEEP total ​

Where:

P vent P_{\text{vent}} P vent ​ is the airway pressure delivered by the mechanical ventilator.

P mus P_{\text{mus}} P mus ​ is the pressure generated by the patient's inspiratory muscles (negative pleural pressure drop).

V ˙ \dot{V} V ˙ is the instantaneous inspiratory gas flow rate.

R aw R_{\text{aw}} R aw ​ is the frictional airway resistance (primarily endotracheal tube and conducting airways).

V V V is the delivered volume above functional residual capacity.

C rs C_{\text{rs}} C rs ​ is the static compliance of the total respiratory system (lungs and chest wall combined).

PEEP total \text{PEEP}_{\text{total}} PEEP total ​ is the sum of applied extrinsic positive end-expiratory pressure ( PEEP e \text{PEEP}_{\text{e}} PEEP e ​ ) and intrinsic or auto-PEEP ( PEEP i \text{PEEP}_{\text{i}} PEEP i ​ ).

The Classification of Phase Variables

A mechanical breath is systematically defined by four distinct phase variables that regulate its lifecycle:

Trigger Variable (Initiation): Determines what signals the ventilator to initiate inspiratory flow. In controlled breaths, the trigger is elapsed time based on the set respiratory frequency. In assisted or spontaneous breaths, inspiration is triggered by patient effort sensing a drop in airway pressure (pressure triggering, typically − 1 to − 2 cmH 2 O -1\text{ to }-2\text{ cmH}_2\text{O} − 1 to − 2 cmH 2 ​ O ) or a deviation in baseline circuit flow (flow triggering, typically 1 to 3 L/min 1\text{ to }3\text{ L/min} 1 to 3 L/min ). Flow triggering markedly reduces triggering work of breathing because continuous circuit base flow satisfies initial patient inspiratory flow demand before mechanical valve actuation.

Target / Control Variable (Delivery): The primary physical parameter governed during inspiration. The ventilator controls either volume (and flow) or pressure . One parameter is held constant while the other becomes the dependent variable determined by respiratory mechanics ( R aw R_{\text{aw}} R aw ​ and C rs C_{\text{rs}} C rs ​ ).

Limit Variable (Constraint): A maximum ceiling value (such as a preset pressure, flow, or volume) that inspiratory delivery cannot exceed during the inspiratory phase. Reaching a limit does not terminate the breath; delivery continues constrained at that ceiling until the cycle criterion is achieved.

Cycle Variable (Termination): The parameter measured to end inspiration and open the exhalation valve. Breaths can be volume-cycled (delivery of target V t V_t V t ​ ), time-cycled (completion of a set inspiratory time T i T_i T i ​ ), or flow-cycled (decay of inspiratory flow to a specific threshold percentage of peak flow).

• 2. Conventional Mandatory Modes: VC-CMV vs PC-CMV
• Volume-Controlled Continuous Mandatory Ventilation (VC-CMV)

In Volume Control (VC-CMV) , the clinician presets a guaranteed tidal volume ( V t V_t V t ​ ), a set respiratory rate, and a specific inspiratory flow rate and pattern (constant square wave vs decelerating ramp wave). Every breath delivers the specified volume unless an upper airway pressure limit alarm is encountered.

Inspiratory Flow Profiles:

Square (constant) flow: Delivers flow at a steady rate throughout inspiration. This enables direct bedside calculation of airway resistance because flow is constant at the moment of peak airway pressure.

Decelerating ramp flow: Flow starts at a maximum peak and linearly decelerates. Decelerating flow delivers the bulk of volume early in inspiration when patient flow demand is greatest, resulting in a lower peak inspiratory pressure ( P peak P_{\text{peak}} P peak ​ ), improved alveolar gas distribution, and higher mean airway pressure ( P mean P_{\text{mean}} P mean ​ ) for a given tidal volume.

Respiratory Mechanics Assessment in VC-CMV: Performing an end-inspiratory hold (pause) maneuver for 0.5 – 1.0 s 0.5\text{--}1.0\text{ s} 0.5 – 1.0 s closes both inspiratory and expiratory valves at end-inspiration when flow decays to zero. Airway pressure drops from P peak P_{\text{peak}} P peak ​ to the plateau pressure ( P plat P_{\text{plat}} P plat ​ ) :

R aw = P peak − P plat V ˙ R_{\text{aw}} = \frac{P_{\text{peak}} - P_{\text{plat}}}{\dot{V}} R aw ​ = V ˙ P peak ​ − P plat ​ ​

C stat = V t P plat − PEEP total C_{\text{stat}} = \frac{V_t}{P_{\text{plat}} - \text{PEEP}_{\text{total}}} C stat ​ = P plat ​ − PEEP total ​ V t ​ ​

Δ P = P plat − PEEP total \Delta P = P_{\text{plat}} - \text{PEEP}_{\text{total}} Δ P = P plat ​ − PEEP total ​

Where Δ P \Delta P Δ P is the driving pressure . Clinical trial evidence indicates that limiting driving pressure to < 14 – 15 cmH 2 O < 14\text{--}15\text{ cmH}_2\text{O} < 14 – 15 cmH 2 ​ O strongly correlates with reduced mortality in acute respiratory distress syndrome (ARDS).

Note

A sudden increase in P peak P_{\text{peak}} P peak ​ with an unchanged P plat P_{\text{plat}} P plat ​ indicates an isolated increase in resistive work (e.g., endotracheal tube kinking, mucous plugging, biting, or acute bronchospasm). Conversely, a concurrent rise in both P peak P_{\text{peak}} P peak ​ and P plat P_{\text{plat}} P plat ​ indicates decreased respiratory system compliance (e.g., tension pneumothorax, worsening ARDS, pulmonary edema, pleural effusion, or abdominal compartment syndrome).

Pressure-Controlled Continuous Mandatory Ventilation (PC-CMV)

In Pressure Control (PC-CMV) , the clinician sets an inspiratory driving pressure level ( Δ P insp \Delta P_{\text{insp}} Δ P insp ​ above PEEP), a respiratory rate, and an inspiratory time ( T i T_i T i ​ ). The ventilator rapidly pressurizes the circuit to the set pressure and holds it for the duration of T i T_i T i ​ , yielding a characteristic exponentially decelerating flow wave.

Mechanics: The cycle variable is strictly time . Tidal volume is completely dependent on the lung's mechanical properties:

V t ≈ Δ P insp × C rs V_t \approx \Delta P_{\text{insp}} \times C_{\text{rs}} V t ​ ≈ Δ P insp ​ × C rs ​

Clinical Implications: PC-CMV caps maximum alveolar pressure at P PEEP + Δ P insp P_{\text{PEEP}} + \Delta P_{\text{insp}} P PEEP ​ + Δ P insp ​ , avoiding extreme peak pressure spikes if patient compliance abruptly falls. However, tidal volume is unstable. If respiratory system compliance deteriorates (e.g., progressive consolidation or chest wall edema), delivered V t V_t V t ​ drops precipitously, risking severe hypoventilation and acute respiratory acidosis. Conversely, if compliance improves or the patient generates vigorous spontaneous inspiratory effort ( P mus P_{\text{mus}} P mus ​ ), V t V_t V t ​ can soar to dangerous levels ( > 10 – 12 mL/kg > 10\text{--}12\text{ mL/kg} > 10 – 12 mL/kg predicted body weight [PBW]), precipitating volutrauma.

3. Pressure Support Ventilation (PSV)

Pressure Support Ventilation (PSV) is a purely patient-initiated spontaneous mode designed to unload the inspiratory muscles and facilitate weaning. The ventilator provides a preset positive pressure assistance level during inspiration whenever the patient initiates a breath.

Phase Variables:

Trigger: Patient effort (flow or pressure).

Limit: Preset pressure support level ( Δ P supp \Delta P_{\text{supp}} Δ P supp ​ ).

Cycle: Flow decay. Inspiration ends when inspiratory flow decelerates to a preset fraction of peak inspiratory flow, termed the expiratory trigger sensitivity (ETS) or flow cycle criterion, typically configured between 25 % 25\% 25% and 40 % 40\% 40% .

Clinical Pearls and Traps in PSV:

In patients with severe obstructive lung disease (e.g., COPD), prolonged mechanical time constants ( R aw × C rs R_{\text{aw}} \times C_{\text{rs}} R aw ​ × C rs ​ ) delay flow decay. A standard 25 % 25\% 25% cycling criterion causes delayed cycling, extending inspiration into neural exhalation. Increasing the ETS to 40 – 50 % 40\text{--}50\% 40 – 50% terminates the breath earlier, reducing dynamic hyperinflation.

PSV requires intact ventilatory drive and reliable patient triggering. In patients with hemodynamic instability, fluctuating encephalopathy, or neuromuscular weakness, PSV risks severe hypoventilation or apnea unless backup apnea ventilation parameters are rigorously calibrated.

4. Airway Pressure Release Ventilation (APRV)

Airway Pressure Release Ventilation (APRV) is an inverse-ratio, pressure-controlled, time-cycled mode that applies continuous positive airway pressure (CPAP) at an elevated pressure ( P high P_{\text{high}} P high ​ ) with brief periodic releases to a lower pressure ( P low P_{\text{low}} P low ​ ) to augment carbon dioxide clearance. Crucially, unconstrained spontaneous breathing is permitted throughout both P high P_{\text{high}} P high ​ and P low P_{\text{low}} P low ​ . Airway

• Pressure
• ^
• | +-----------------------+ +-----------------------+
• P_high | | (Spontaneous | | |
• | | breathing allowed) | | |
• | | | | |
• | | \ | \
• P_low +---+------------------------+-------+------------------------+---> Time
• <-------- T_high -------><-T_low-> <-------- T_high ------->
• The Open-Lung Concept in APRV

APRV aims to recruit non-aerated lung units and maintain alveolar stability via prolonged sustained pressure:

P high P_{\text{high}} P high ​ : High CPAP level, typically initiated at 20 – 30 cmH 2 O 20\text{--}30\text{ cmH}_2\text{O} 20 – 30 cmH 2 ​ O (or matched to the prior P plat P_{\text{plat}} P plat ​ in conventional ventilation). It sustains recruitment of collapsed dependent lung tissue.

T high T_{\text{high}} T high ​ : Duration of P high P_{\text{high}} P high ​ , typically set between 4.0 and 6.0 s 4.0\text{ and }6.0\text{ s} 4.0 and 6.0 s , creating a duty cycle where 85 % to 95 % 85\%\text{ to }95\% 85% to 95% of the respiratory cycle is spent at P high P_{\text{high}} P high ​ .

P low P_{\text{low}} P low ​ : Set uniformly at 0 cmH 2 O 0\text{ cmH}_2\text{O} 0 cmH 2 ​ O to optimize the driving pressure gradient and maximize instantaneous gas egress during the brief release phase.

T low T_{\text{low}} T low ​ (Release Time): Set between 0.4 and 0.8 s 0.4\text{ and }0.8\text{ s} 0.4 and 0.8 s .

The 75% Expiratory Flow Truncation Rule

The fundamental physiologic principle in APRV is that T low T_{\text{low}} T low ​ must be individualized by inspecting the expiratory flow-time scalar . T low T_{\text{low}} T low ​ must be set short enough so that expiratory flow terminates when it reaches 75 % 75\% 75% of the peak expiratory flow (PEF) (i.e., terminating when E term / PEF = 0.75 E_{\text{term}} / \text{PEF} = 0.75 E term ​ / PEF = 0.75 ).

Warning

Truncating the release phase at 75 % 75\% 75% of peak expiratory flow creates intentional dynamic gas trapping that generates functional intrinsic PEEP, preventing alveolar derecruitment and cyclical atelectotrauma. If T low T_{\text{low}} T low ​ is set too long ( E term < 50 % PEF E_{\text{term}} < 50\%\text{ PEF} E term ​ < 50% PEF ), the lung empties completely to atmospheric pressure, resulting in catastrophic end-expiratory alveolar collapse, shear stress, and hypoxemia.

Contraindications to APRV: Severe chronic obstructive pulmonary disease or acute status asthmaticus (high baseline airflow limitation causes profound uncontrolled hyperinflation) and acute severe intracranial hypertension (high mean intrathoracic pressure impairs cerebral venous return and elevates intracranial pressure).

5. Advanced Proportional Modes: PAV+ and NAVA

Conventional modes deliver a fixed output regardless of instantaneous neuromuscular effort. In contrast, advanced closed-loop proportional modes synchronize ventilator assistance directly with patient effort in real time.

Proportional Assist Ventilation with Load-Adjustable Gain Factors (PAV+)

PAV+ continuously estimates patient respiratory mechanics using automated, imperceptible 300 ms 300\text{ ms} 300 ms occlusions every 4 to 10 breaths to calculate instantaneous elastance ( E rs E_{\text{rs}} E rs ​ ) and resistance ( R aw R_{\text{aw}} R aw ​ ).

The clinician sets a percentage of assistance (e.g., 60 % to 70 % 60\%\text{ to }70\% 60% to 70% support).

The ventilator instantaneously adjusts P vent P_{\text{vent}} P vent ​ in direct proportion to patient muscular effort ( P mus P_{\text{mus}} P mus ​ ), obeying the equation of motion:

P vent ( t ) = % Gain × [ V ( t ) × E rs + V ˙ ( t ) × R aw ] P_{\text{vent}}(t) = \%\text{Gain} \times \left[ V(t) \times E_{\text{rs}} + \dot{V}(t) \times R_{\text{aw}} \right] P vent ​ ( t ) = % Gain × [ V ( t ) × E rs ​ + V ˙ ( t ) × R aw ​ ]

Clinical Benefit: Prevents both over-assistance (which induces diaphragmatic disuse atrophy) and under-assistance (which leads to fatigue), promoting physiologic breathing patterns.

Neurally Adjusted Ventilatory Assist (NAVA)

NAVA utilizes a specialized nasogastric or orogastric feeding tube embedded with an array of miniaturized bipolar electromyographic (EMG) electrodes positioned across the crural diaphragm. This catheter captures the electrical activity of the diaphragm (Edi) , measured in microvolts ( μ V \mu\text{V} μ V ).

Mechanics: The Edi signal represents pure central neural output from the respiratory center, preceding diaphragmatic contraction and airflow by 50 – 100 ms 50\text{--}100\text{ ms} 50 – 100 ms .

Triggering: Triggered immediately when Edi rises > 0.5 μ V > 0.5\,\mu\text{V} > 0.5 μ V above baseline, bypassing pneumatic trigger delays, pneumatic leaks, and auto-PEEP thresholds.

Delivery: Airway pressure is delivered in direct proportion to Edi:

P vent = NAVA Level × ( Edi − Edi min ) + PEEP P_{\text{vent}} = \text{NAVA Level} \times (\text{Edi} - \text{Edi}_{\text{min}}) + \text{PEEP} P vent ​ = NAVA Level × ( Edi − Edi min ​ ) + PEEP

Cycling: Cycles off when the Edi signal drops to 70 % 70\% 70% of its peak value, ensuring near-perfect neural-mechanical cycle synchrony.

Clinical Benefit: NAVA operates independently of airway leaks, making it particularly valuable in noninvasive ventilation, bronchopleural fistulas, and pediatric critical care where pneumatically triggered modes suffer massive dyssynchrony.

6. Comprehensive Ventilator Mode Comparison

Mode Trigger Variable Limit Variable Cycle Variable Key Operator Settings Primary Clinical Advantages Primary Disadvantages & Risks

VC-CMV Time or Patient (Flow/Pressure) Flow & Volume Volume (or Time) V t V_t V t ​ , Set Rate, Flow Rate, Flow Waveform, PEEP, FiO 2 \text{FiO}_2 FiO 2 ​ Guaranteed minute ventilation; direct calculation of C stat C_{\text{stat}} C stat ​ and R aw R_{\text{aw}} R aw ​ . Variable peak pressures; flow starvation if flow is set below patient demand.

PC-CMV Time or Patient (Flow/Pressure) Pressure Time Δ P insp \Delta P_{\text{insp}} Δ P insp ​ , Inspiratory Time ( T i T_i T i ​ ), Set Rate, PEEP, FiO 2 \text{FiO}_2 FiO 2 ​ Limits peak alveolar pressure; decelerating flow improves gas distribution. Unstable V t V_t V t ​ ; hypoventilation if compliance falls; volutrauma if compliance improves.

PSV Patient (Flow/Pressure) Pressure Flow (% of Peak Flow) Δ P supp \Delta P_{\text{supp}} Δ P supp ​ , PEEP, Expiratory Trigger Sensitivity (ETS), FiO 2 \text{FiO}_2 FiO 2 ​ Preserves diaphragmatic function; lowers sedation needs; patient controls rate and T i T_i T i ​ . Apnea risk in unstable patients; cycle dyssynchrony in severe obstructive airway disease.

APRV Time (Spontaneous breaths triggered by patient) Pressure Time P high P_{\text{high}} P high ​ , P low P_{\text{low}} P low ​ , T high T_{\text{high}} T high ​ , T low T_{\text{low}} T low ​ , FiO 2 \text{FiO}_2 FiO 2 ​ Maximizes alveolar recruitment; lowers peak pressures; preserves spontaneous breathing. Risk of severe alveolar collapse if T low T_{\text{low}} T low ​ is excessive; contraindicated in COPD and elevated ICP.

PAV+ Patient (Flow/Pressure) Pressure / Flow Flow % Assist Gain, PEEP, FiO 2 \text{FiO}_2 FiO 2 ​ Dynamic proportional assist; tracks changing patient effort; prevents muscle atrophy. Requires reliable patient effort; inaccurate if large endotracheal tube leaks exist.

NAVA Neural (Diaphragm EMG Edi ≥ 0.5 μ V \ge 0.5\,\mu\text{V} ≥ 0.5 μ V ) Pressure Neural (Edi decay to 70% of peak) NAVA Level, PEEP, Backup Ventilation Settings, FiO 2 \text{FiO}_2 FiO 2 ​ Bypasses pneumatic trigger/cycle delays; immune to circuit leaks; ideal synchrony. Requires dedicated Edi catheter; unreliable in severe phrenic nerve injury or neuromuscular blockade.

7. Board Exam High-Yield Summary

Tip

Driving Pressure Target: Always prioritize driving pressure Δ P = P plat − PEEP < 14 – 15 cmH 2 O \Delta P = P_{\text{plat}} - \text{PEEP} < 14\text{--}15\text{ cmH}_2\text{O} Δ P = P plat ​ − PEEP < 14 – 15 cmH 2 ​ O over tidal volume alone when titrating ventilation in ARDS.

Flow Starvation in VC: When a patient pulls against a preset volume-control flow, the pressure-time curve scallops downward ("dishout"). Fix this by increasing the peak flow rate, converting to a decelerating ramp, or switching to pressure control.

APRV T_low Titration: The termination of the release phase in APRV must strictly occur at 75 % 75\% 75% of peak expiratory flow to retain sufficient auto-PEEP and maintain alveolar stability.